MeSH term
Frequency | Condition_Probility | *Education, Medical, Graduate | 2 | 6.0 |
*Educational Status | 2 | 6.0 |
Humans | 190 | 0.0 |
*Students, Medical | 2 | 5.0 |
Surgery/*education | 2 | 5.0 |
Adult | 72 | 0.0 |
Aged | 40 | 0.0 |
Aged, 80 and over | 13 | 0.0 |
Female | 90 | 0.0 |
Male | 96 | 0.0 |
Middle Aged | 74 | 0.0 |
Peritoneum/*metabolism | 2 | 16.0 |
beta 2-Microglobulin/analysis | 9 | 7.0 |
Age Factors | 5 | 0.0 |
Cell Cycle | 2 | 0.0 |
Prognosis | 19 | 0.0 |
Prospective Studies | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 79 | 0.0 |
Risk Factors | 5 | 0.0 |
Survival Analysis | 8 | 0.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
*Bone Marrow Transplantation | 4 | 1.0 |
Chromosome Aberrations | 2 | 0.0 |
Combined Modality Therapy | 7 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
Survival Rate | 6 | 0.0 |
Time Factors | 12 | 0.0 |
Transplantation, Autologous | 6 | 1.0 |
Animals | 30 | 0.0 |
Comparative Study | 38 | 0.0 |
Mice | 20 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reference Values | 10 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Amyloidosis/*etiology | 2 | 25.0 |
Chronic Disease | 6 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Treatment Outcome | 9 | 0.0 |
Tumor Markers, Biological/*blood | 5 | 1.0 |
beta 2-Microglobulin/*analysis | 35 | 46.0 |
Amino Acid Sequence | 9 | 0.0 |
Chickens/*genetics | 2 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Species Specificity | 6 | 0.0 |
Blotting, Western | 2 | 0.0 |
*Cation Transport Proteins | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Intestinal Absorption | 2 | 1.0 |
*Iron-Binding Proteins | 2 | 5.0 |
Mice, Knockout | 3 | 0.0 |
beta 2-Microglobulin/deficiency/genetics | 2 | 33.0 |
Amyloid/*metabolism | 2 | 3.0 |
Renal Dialysis/*adverse effects | 5 | 3.0 |
beta 2-Microglobulin/*metabolism | 18 | 42.0 |
English Abstract | 17 | 0.0 |
Follow-Up Studies | 10 | 0.0 |
Prevalence | 3 | 0.0 |
beta 2-Microglobulin/urine | 9 | 40.0 |
Adolescent | 17 | 0.0 |
Child | 16 | 0.0 |
ROC Curve | 2 | 1.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
alpha-Fetoproteins/*analysis | 2 | 0.0 |
*Membranes, Artificial | 4 | 4.0 |
*Renal Dialysis | 5 | 1.0 |
Mice, Mutant Strains | 2 | 0.0 |
Phenotype | 4 | 0.0 |
beta 2-Microglobulin/*genetics | 8 | 42.0 |
Blotting, Northern | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
beta 2-Microglobulin/*blood | 7 | 70.0 |
*HIV-1 | 3 | 0.0 |
Solubility | 5 | 0.0 |
Adsorption | 3 | 1.0 |
Base Sequence | 11 | 0.0 |
Molecular Sequence Data | 12 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Disease Progression | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Flow Cytometry | 5 | 0.0 |
Alleles | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Cell Line | 10 | 0.0 |
Histocompatibility Antigens Class I/*immunology | 2 | 1.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Acetylglucosaminidase/*urine | 2 | 40.0 |
Creatinine/urine | 5 | 4.0 |
Infant | 12 | 0.0 |
beta 2-Microglobulin/*urine | 9 | 64.0 |
Chromosome Mapping | 4 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Proportional Hazards Models | 4 | 0.0 |
Melphalan/administration & dosage | 3 | 6.0 |
Multivariate Analysis | 4 | 0.0 |
Cebidae/*genetics | 2 | 15.0 |
Consensus Sequence | 2 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Selection (Genetics) | 2 | 1.0 |
Haplotypes | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Child, Preschool | 12 | 0.0 |
Multiple Myeloma/*blood/*therapy | 2 | 40.0 |
Infant, Newborn | 6 | 0.0 |
beta 2-Microglobulin/*immunology | 4 | 16.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Aging | 2 | 0.0 |
Gestational Age | 2 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 3 | 0.0 |
Amyloid/*analysis | 2 | 5.0 |
Renal Dialysis | 3 | 0.0 |
Biological Markers | 5 | 0.0 |
Creatinine/blood | 9 | 2.0 |
Molecular Weight | 5 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Biological Markers/urine | 5 | 7.0 |
Kidney Diseases/*diagnosis | 2 | 50.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
Biopterin/analogs & derivatives/blood | 3 | 6.0 |
Neopterin | 7 | 7.0 |
beta 2-Microglobulin/metabolism | 3 | 3.0 |
Gene Expression | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Pregnancy | 3 | 0.0 |
Multiple Myeloma/*drug therapy | 2 | 12.0 |
Blood Pressure | 2 | 0.0 |
beta 2-Microglobulin/drug effects/*metabolism | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Regression Analysis | 4 | 0.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Glomerular Filtration Rate | 3 | 2.0 |
*Smoking | 2 | 2.0 |
Biopterin/*analogs & derivatives/blood | 3 | 13.0 |
Blood Proteins/analysis | 2 | 1.0 |
Cohort Studies | 4 | 0.0 |
Blood Urea Nitrogen | 2 | 3.0 |
Phylogeny | 2 | 0.0 |
Infant, Premature | 2 | 1.0 |
Kidney/*physiology | 2 | 4.0 |
Acetylglucosaminidase/urine | 4 | 22.0 |
Aminopeptidases/urine | 2 | 66.0 |
Antigens, CD13 | 2 | 3.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Interferon Type II/blood | 2 | 1.0 |
Radioimmunoassay | 6 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Cattle | 2 | 0.0 |
Exons | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
DNA/genetics | 2 | 0.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Muramidase/urine | 2 | 66.0 |
Retinol-Binding Proteins/urine | 2 | 22.0 |
Cell Membrane/immunology | 2 | 0.0 |
Kidney Diseases/*chemically induced | 2 | 28.0 |
Cells, Cultured | 4 | 0.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 4 | 3.0 |
Biopsy | 3 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
Retinol-Binding Proteins/*urine | 2 | 25.0 |
Blotting, Southern | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
beta 2-Microglobulin/*cerebrospinal fluid | 3 | 50.0 |
Dexamethasone/administration & dosage | 2 | 6.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Stimulation, Chemical | 2 | 0.0 |
Creatinine/blood/urine | 2 | 9.0 |
Proteinuria | 2 | 5.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
HIV Infections/*immunology | 2 | 0.0 |
Lymphocytes/*immunology | 2 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Cellulose | 2 | 16.0 |
Dialysis Solutions | 2 | 11.0 |
*Kidney Function Tests | 2 | 16.0 |
Cellulose/analogs & derivatives | 3 | 10.0 |
Methylmethacrylates | 2 | 18.0 |
Bacterial Infections/*immunology | 2 | 6.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Leukotriene B4/metabolism | 2 | 11.0 |
Membranes, Artificial | 2 | 2.0 |
Peritonitis/*immunology | 2 | 28.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Cytokines | 2 | 1.0 |
Acute Disease | 3 | 0.0 |
Kidney Function Tests | 2 | 1.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Injections, Spinal | 2 | 5.0 |
Leukocyte Count | 2 | 0.0 |
Acrylic Resins | 2 | 8.0 |
Dialysis Solutions/analysis | 2 | 18.0 |
Polymers | 3 | 2.0 |
Sulfones | 3 | 15.0 |
Transcription, Genetic | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
RNA/analysis | 2 | 0.0 |
Chemistry | 3 | 1.0 |
Kidney/physiopathology | 2 | 3.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Transfection | 2 | 0.0 |
Extracellular Space/physiology | 2 | 12.0 |
beta 2-Microglobulin/*analysis/urine | 3 | 100.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
HLA Antigens/*analysis | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
HLA Antigens/*immunology | 2 | 0.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Immunoelectrophoresis | 3 | 1.0 |
Isoelectric Point | 2 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Lymphocyte Activation | 3 | 0.0 |
Adenocarcinoma/*metabolism/pathology | 2 | 1.0 |
Kidney Neoplasms/*metabolism/pathology | 2 | 6.0 |
*Glomerular Filtration Rate | 2 | 8.0 |
Kidney Transplantation | 2 | 1.0 |
Beta-Globulins/*immunology | 2 | 25.0 |
Beta-Globulins/*analysis | 7 | 17.0 |
RNA, Messenger/analysis | 2 | 0.0 |
